Prediction of Long-Term Diabetes Remission After RYGB, Sleeve Gastrectomy, and Adjustable Gastric Banding Using DiaRem and Advanced-DiaRem Scores

  • Dror DickerEmail author
  • Rachel Golan
  • Judith Aron-Wisnewsky
  • Jean-Daniel Zucker
  • Natalyia Sokolowska
  • Doron S. Comaneshter
  • Rina Yahalom
  • Shlomo Vinker
  • Karine Clément
  • Assaf Rudich
Original Contributions



DiaRem is a clinical scoring system designed to predict diabetes remission (DR) 1-year post-Roux-en-Y gastric bypass (RYGB). We examined long-term (2- and 5-year) postoperative DR prediction by DiaRem and an advanced-DiaRem (Ad-DiaRem) score following RYGB, sleeve gastrectomy (SG), and gastric banding (GB).


We accessed data from a computerized database of persons with type 2 diabetes and BMI ≥ 30 kg/m2 who underwent RYGB, SG, or GB, and determined DR status 2- and 5-year postoperative according to preoperative DiaRem and the Ad-DiaRem calculated scores.


Among 1459 patients with 5-year postoperative diabetes status data, 53.6% exhibited DR. For RYGB, Ad-DiaRem trended to exhibit mildly improved predictive capacity 5-year postoperatively compared to DiaRem: Areas under receiver operating characteristic [AUROC] curves were 0.85 (0.76–0.93) and 0.78 (0.69–0.88), respectively. The positive predictive values (PPVs) detecting > 80% of those achieving DR (i.e., sensitivity ≥ 0.8) were 78.2% and 73.2%, respectively, and higher Ad-DiaRem scores more consistently associated with decreased DR rates. Following SG, both scores had an AUROC of 0.82, but Ad-DiaRem still had a higher PPV for predicting > 80% of those with 5-year postoperative DR (76.2% and 71.0%). Predictive capacity parameters were comparatively lower, for both scores, when considering DR 5-year post-GB (AUROC: 0.73 for both scores, PPV: 66.3% and 64.3%, respectively).


Ad-DiaRem provides modest improvement compared to DiaRem in predicting long-term DR 5-years post-RYGB. Both scores similarly provide fair predictive capacity for 5-year postoperative DR after SG.


Diabetes remission Bariatric surgery Prediction score 



We thank Dr. Tal Pecht, Dr. Ilana Harman-Boehm, and Dr. Ilya Polischuck for their support and excellent discussions that contributed to this work. Dr. Dror Dicker is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Author Contribution

DD planned the study, researched the data, reviewed and edited the manuscript, and added to the discussion; RG researched the data and wrote the manuscript; JAW planned the study, researched the data, reviewed and edited the manuscript, and added to the discussion; JDZ researched the data and reviewed the manuscript; NS researched the data; DSC researched the data; RY researched the data; SV researched the data; KC planned the study, researched the data, and reviewed the manuscript; AR planned the study, researched the data, and wrote the manuscript.

Funding information

This study was supported in part by grants from the Ministry of Science, Technology & Space, Israel (Israeli-French collaboration) and by The Ministe’re de L’Education National, de l’Enseignement Sup’erieur et de la Recherche, France (Maimonide “Franco-Israeli project”).

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed Consent

Informed consent was waived by the ethical committee that approved this study.

Supplementary material

11695_2018_3583_MOESM1_ESM.docx (13 kb)
Supplemental Table 1 (DOCX 12 kb)
11695_2018_3583_MOESM2_ESM.docx (18 kb)
Supplemental Table 2 (DOCX 18 kb)
11695_2018_3583_MOESM3_ESM.pptx (158 kb)
Supplemental Figure 1 (PPTX 157 kb)
11695_2018_3583_MOESM4_ESM.pptx (203 kb)
Supplemental Figure 2 (PPTX 202 kb)
11695_2018_3583_MOESM5_ESM.pptx (194 kb)
Supplemental Figure 3 (PPTX 193 kb)
11695_2018_3583_MOESM6_ESM.pptx (283 kb)
Supplemental Figure 4 (PPTX 283 kb)


  1. 1.
    Dicker D, Yahalom R, Comaneshter DS, et al. Long-term outcomes of three types of bariatric surgery on obesity and type 2 diabetes control and remission. Obes Surg. 2016;26(8):1814–20.CrossRefGoogle Scholar
  2. 2.
    Vest AR, Heneghan HM, Agarwal S, et al. Bariatric surgery and cardiovascular outcomes: a systematic review. Heart. 2012;98(24):1763–77.CrossRefGoogle Scholar
  3. 3.
    Adams TD, Davidson LE, Litwin SE, et al. Weight and metabolic outcomes 12 years after gastric bypass. N Engl J Med. 2017;377(12):1143–55.CrossRefGoogle Scholar
  4. 4.
    Angrisani L, Santonicola A, Iovino P, et al. Bariatric surgery worldwide 2013. Obes Surg. 2015;25(10):1822–32.CrossRefGoogle Scholar
  5. 5.
    Aminian A, Brethauer SA, Andalib A, et al. Individualized metabolic surgery score: procedure selection based on diabetes severity. Ann Surg. 2017;266(4):650–7.CrossRefGoogle Scholar
  6. 6.
    Lee WJ, Hur KY, Lakadawala M, et al. Predicting success of metabolic surgery: age, body mass index, C-peptide, and duration score. Surg Obes Relat Dis. 2013;9(3):379–84.CrossRefGoogle Scholar
  7. 7.
    Still CD, Wood GC, Benotti P, et al. Preoperative prediction of type 2 diabetes remission after Roux-en-Y gastric bypass surgery: a retrospective cohort study. Lancet Diabetes Endocrinol. 2014;2(1):38–45.CrossRefGoogle Scholar
  8. 8.
    Aron-Wisnewsky J, Sokolovska N, Liu Y, et al. The advanced-DiaRem score improves prediction of diabetes remission 1 year post-Roux-en-Y gastric bypass. Diabetologia. 2017;60(10):1892–902.CrossRefGoogle Scholar
  9. 9.
    Cotillard A, Poitou C, Duchateau-Nguyen G, et al. Type 2 diabetes remission after gastric bypass: what is the best prediction tool for clinicians? Obes Surg. 2015;25(7):1128–32.CrossRefGoogle Scholar
  10. 10.
    Aminian A, Brethauer SA, Andalib A, Nowacki AS, Jimenez A, Corcelles R, et al. Individualized metabolic surgery score: procedure selection based on diabetes severity. Ann Surg 2017.Google Scholar
  11. 11.
    Lee MH, Lee WJ, Chong K, et al. Predictors of long-term diabetes remission after metabolic surgery. J Gastrointest Surg. 2015;19(6):1015–21.CrossRefGoogle Scholar
  12. 12.
    Wood GC, Mirshahi T, Still CD, et al. Association of DiaRem score with cure of type 2 diabetes following bariatric surgery. JAMA Surg. 2016;151(8):779–81.CrossRefGoogle Scholar
  13. 13.
    Lee WJ, Chong K, Chen SC, et al. Preoperative prediction of type 2 diabetes remission after gastric bypass surgery: a comparison of DiaRem scores and ABCD scores. Obes Surg. 2016;26(10):2418–24.CrossRefGoogle Scholar
  14. 14.
    Craig Wood G, Horwitz D, Still CD, et al. Performance of the DiaRem score for predicting diabetes remission in two health systems following bariatric surgery procedures in Hispanic and non-Hispanic white patients. Obes Surg. 2018;28(1):61–8.CrossRefGoogle Scholar
  15. 15.
    Aminian A, Brethauer SA, Kashyap SR, et al. DiaRem score: external validation. Lancet Diabetes Endocrinol. 2014;2(1):12–3.CrossRefGoogle Scholar
  16. 16.
    Mehaffey JH, Mullen MG, Mehaffey RL, et al. Type 2 diabetes remission following gastric bypass: does DiaRem stand the test of time? Surg Endosc. 2017;31(2):538–42.CrossRefGoogle Scholar
  17. 17.
    Tharakan G, Scott R, Szepietowski O, et al. Limitations of the DiaRem score in predicting remission of diabetes following Roux-En-Y gastric bypass (RYGB) in an ethnically diverse population from a single institution in the UK. Obes Surg. 2017;27(3):782–6.CrossRefGoogle Scholar
  18. 18.
    Fried M, Yumuk V, Oppert JM, et al. Interdisciplinary European Guidelines on metabolic and bariatric surgery. Obes Facts. 2013;6(5):449–68.CrossRefGoogle Scholar
  19. 19.
    Buse JB, Caprio S, Cefalu WT, et al. How do we define cure of diabetes? Diabetes Care. 2009;32(11):2133–5.CrossRefGoogle Scholar
  20. 20.
    Liu Y, Aron-Wisnewsky J, Marcelin G, et al. Accumulation and changes in composition of collagens in subcutaneous adipose tissue after bariatric surgery. J Clin Endocrinol Metab. 2016;101(1):293–304.CrossRefGoogle Scholar
  21. 21.
    Dixon JB, O'Brien PE, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA. 2008;299(3):316–23.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Dror Dicker
    • 1
    • 2
    Email author
  • Rachel Golan
    • 3
  • Judith Aron-Wisnewsky
    • 4
    • 5
    • 6
  • Jean-Daniel Zucker
    • 7
    • 8
  • Natalyia Sokolowska
    • 4
    • 5
    • 6
  • Doron S. Comaneshter
    • 9
  • Rina Yahalom
    • 9
  • Shlomo Vinker
    • 9
  • Karine Clément
    • 4
    • 5
    • 6
  • Assaf Rudich
    • 10
  1. 1.Department of Internal Medicine D, Hasharon HospitalRabin Medical CenterPetah TikvaIsrael
  2. 2.Sackler School of MedicineTel Aviv UniversityTel AvivIsrael
  3. 3.Department of Public Health, Faculty of Health SciencesBen-Gurion University of the NegevBeer-ShevaIsrael
  4. 4.Institute of Cardiometabolism and Nutrition, ICAN, Assistance Publique Hôpitaux de ParisPitié-Salpêtrière hospitalParisFrance
  5. 5.INSERM, UMR S U1166Nutriomics TeamParisFrance
  6. 6.Sorbonne UniversitésUPMC University ParisParisFrance
  7. 7.Institute of Cardiometabolism and Nutrition, ICAN, Integromics team, Assistance Publique Hôpitaux de ParisPitié-Salpêtrière hospitalParisFrance
  8. 8.Sorbonne Universités, UPMC Univ Paris 06, IHU ICAN, IRD, unité de modélisation mathématique et informatique des systèmes complexes (UMMISCO)BondyFrance
  9. 9.Central Headquarters, Clalit Health ServicesTel AvivIsrael
  10. 10.Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, and the National Institute of Biotechnology in the NegevBen-Gurion University of the NegevBeer-ShevaIsrael

Personalised recommendations